ITGA11抗体

+ +

•  

   

     Gel: 6%SDS-PAGE, Lysate: 40 μg, Lane 1-5: A549, Hela, HepG2, 293T, K562 cell lysates, Primary antibody: P04974(ITGA11 Antibody) at dilution 1/400, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 40 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using P04974(ITGA11 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P04974(ITGA11 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

The ITGA11 antibody targets integrin alpha-11 (ITGA11), a transmembrane glycoprotein that pairs with integrin beta-1 (ITGB1) to form the α11β1 collagen receptor. ITGA11 is a member of the integrin family, which mediates cell-extracellular matrix (ECM) interactions, influencing cellular adhesion, migration, and signaling. Specifically, α11β1 binds collagen types IV and VI, playing roles in tissue development, wound healing, and fibrosis. ITGA11 is highly expressed in mesenchymal stromal cells, fibroblasts, and certain cancers, where it contributes to tumor progression, stromal remodeling, and metastasis.

Research on ITGA11 antibodies has gained momentum due to their potential applications in studying fibrosis and cancer biology. In fibrotic diseases (e.g., lung or liver fibrosis), ITGA11 overexpression correlates with excessive collagen deposition and tissue stiffening. In cancers, ITGA11 promotes invasion and angiogenesis by modulating tumor-stroma crosstalk. Antibodies against ITGA11 enable detection of its expression in tissues (via IHC, IF, or flow cytometry) or functional blocking in vitro/in vivo models to dissect its mechanistic roles.

Commercial ITGA11 antibodies are typically monoclonal or polyclonal, validated for specificity in human, mouse, or rat samples. Their development supports translational studies exploring ITGA11 as a diagnostic biomarker or therapeutic target. However, challenges remain in standardizing antibody validation and understanding isoform-specific functions. Ongoing research aims to clarify ITGA11's dual roles in homeostasis and pathology, driving interest in targeted therapies for fibrosis and cancer.